Dr. George is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
195 Little Albany Street
New Brunswick, NJ 08901Phone+1 732-235-9692Fax+1 732-235-7110
Summary
- Dr. Mridula George is an oncologist in New Brunswick, NJ and is affiliated with Rutgers Cancer Institute of New Jersey. She received her medical degree from Rutgers Robert Wood Johnson Medical School and has been in practice 5 years. She specializes in breast cancer and hematologic oncology.
Education & Training
Rutgers Health/Robert Wood Johnson Medical SchoolFellowship, Hematology and Medical Oncology, 2015 - 2018
UMass Chan Medical SchoolResidency, Internal Medicine, 2012 - 2015
Rutgers Robert Wood Johnson Medical SchoolClass of 2012
Certifications & Licensure
NJ State Medical License 2015 - 2025
MA State Medical License 2012 - 2015- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer Start of enrollment: 2019 Nov 20
- A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study Start of enrollment: 2020 Jun 10
- INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study Start of enrollment: 2020 Jul 13
Publications & Presentations
PubMed
- Survivorship care plans and adherence to breast and cervical cancer screening guidelines among cancer survivors in a national sample.Marco Santos-Teles, Ganesh Modugu, Isabel C Silva, Elisa V Bandera, Mridula George
Supportive Care in Cancer. 2024-11-18 - Real-world treatment patterns of adjuvant endocrine therapy and ovarian suppression in premenopausal HR+/HER2+ breast cancer.Jasmine S Sukumar, Sagar Sardesai, Andy Ni, Nicole Williams, Kai Johnson
Cancer Medicine. 2024-06-01 - 2 citationsOvarian Suppression: Early Menopause, Late Effects.Chaya Goldberg, Megan R Greenberg, Alexandra Noveihed, Laila Agrawal, Coral Omene
Current Oncology Reports. 2024-05-01
Press Mentions
Natera to Present New SignateraTM Data in Multiple Abstracts at the San Antonio Breast Cancer SymposiumNovember 25th, 2024- Psychosocial Screening Should Be Part of Breast Cancer SurvivorshipJanuary 10th, 2022
- New Pharma Trials Making Big Gains in Fight Against Triple-Negative Breast Cancer (TNBC)December 16th, 2020
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
